The LKB1 gene, also known as STK11, maps to the chromosomal region 19p13.3, which is frequently lost in several types of cancer. The gene spans 23 kb and is made up of nine coding exons and a final noncoding exon. LKB1 encodes for an mRNA of B2.4 kb transcribed in a telomere-to-centromere direction and for a protein of 433 amino acids and approximately 48 kDa . The protein, which has serine-threonine kinase activity, possesses a nuclear localization signal in the N-terminal noncatalytic region (residues 38-43) and a kinase domain (residues 49-309) (Alessi et al., 2006) . Although LKB1 protein expression is mainly cytoplasmic, it can also be localized in the nucleus.
LKB1 is widely expressed in embryonic and adult tissues although at different levels. Early mouse embryos (E7-11) have highly ubiquitous expression in all embryonic and extra-embryonic tissues. During development, LKB1 expression becomes more pronounced in heart, esophagus, pancreas, kidney, colon, lung, small intestine and stomach (Luukko et al., 1999; Rowan et al., 2000) . In adult tissues, levels of LKB1 protein are high in most epithelia, in the follicles and corpus luteum of the ovary, and the seminiferous tubules of the testis, in myocytes from skeletal muscle and in glia cells (Rowan et al., 2000; Conde et al., 2007; Figure 1a ).
LKB1 and Peutz-Jeghers syndrome
Germline mutations of LKB1 cause the autosomal dominant Peutz-Jeghers syndrome (PJS) (OMIM 175200) Jenne et al., 1998) . The type and pattern of these mutations have been extensively reviewed elsewhere (Alessi et al., 2006; Launonen, 2005) . Individuals with PJS typically exhibit mucocutaneous melanin pigmentation and suffer from hamartomatous polyps in the gastrointestinal tract (Jeghers et al., 1949; Giardiello et al., 2000) . However, among the most important associated health-related concerns is the increased risk of cancer development (Giardiello et al., 2000) . Gastrointestinal tumors are the most commonly diagnosed malignancies in PJS patients, but the risk of developing cancer from other origins is also significantly higher (Figure 1b) (Giardiello et al., 2000; Hearle et al., 2006a) . To some extent, the pattern of tumor susceptibility in PJS patients recapitulates the expression of LKB1 in normal adult and embryonic tissues. For example, gonadal cell types that derive from the coelomic epithelium (sex cords) or mesenchymal cells of the embryonic gonads include granulosa cells and theca cells, which have very high levels of LKB1 protein (Conde et al., 2007) . Interestingly, a type of ovarian cancer arising from these cell types, the ovarian sex cord tumors with annular tubules, which occurs rarely in the general population, is present at higher frequencies in women with PJS. Likewise, the level of LKB1 immunostaining is moderately high in cells from the breast, epithelia from the small intestine, colon and pancreatic islets from human adult normal tissue, and very high in the small intestine and stomach of human embryos. Tumors from these origins are the commonest types in PJS (Figure 1b ).
Most studies of PJS patients have reported that only about half of the individuals carry LKB1 germline mutations, which suggested that other tumor-suppressor genes must be associated with the syndrome in the remaining patients (Wang et al., 1999a; Alhopuro et al., 2005) . Several chromosomal regions were thought to contain a second PJS locus, such as 19q, but genes within these regions do not contain LKB1 mutations (Buchet-Poyau et al., 2002) . More recently, the use of specific technical approaches, such as multiplex ligationdependent probe amplification, which allows the identification of large-scale gene deletions, has improved the detection of LKB1 alterations in PJS patients by up to 80% (Hearle et al., 2006b; Volikos et al., 2006) . Thus, these results indicate that LKB1 is the main causal gene in PJS, lessening the probability of there being a second PJS locus.
Is LKB1 involved in the carcinogenesis of sporadic tumors? The example of lung cancer As described above, PJS patients have an increased risk of several types of cancer. Unexpectedly, LKB1 is infrequently mutated in most of the tumor types of sporadic origin screened to date. When first identified as the gene responsible for PJS, LKB1 was tested for inactivating mutations in a variety of sporadic tumors. Although tumor-specific LKB1 alterations have been identified in many of these tumor types, their frequency is extremely low. Table 1 summarizes most of the LKB1 mutations found in sporadic cancer to date, including cancer cell lines and primary tumors of various origins. The mutational screening method is also indicated. LKB1 mutations are present in about 4% of pancreatic cancers (cell lines and primary tumors from xenografts), but no mutations have been reported in breast, colorectal or gastric cancer. The exception is non-small-cell lung cancer (NSCLC), in which LKB1 inactivation is a common event (Sanchez-Cespedes et al., 2002; Carretero et al., 2004; Matsumoto et al., 2007) . These differences are puzzling because lung cancer risk is higher but is not among the commonest tumors that occur in PJS. Before ruling out the LKB1 tumor-suppressor role in sporadic tumors other than in lung, the obstacles associated with the detection of mutations in tumors need to be b Stomach a LKB1 PROTEIN EXPRESSION (Luuko et al. 1999; Rowan et al. 2000 Conde et al. 2007 (Giardiello et al.et al. 2000; Lim et al. 2004; Hearle et al. 2006a) 
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M Sanchez-Cespedes considered. These may have adversely affected the detection of LKB1 mutations. In PJS patients, a substantial percentage of LKB1-inactivating events are large deletions (Hearle et al., 2006b; Volikos et al., 2006) , and the same may be the case in sporadic cancer.
If so, such deletions would have gone undetected in a simple mutational screening, masked by normal DNA in primary tumors or mistaken as PCR failures in cancer cell lines. As shown in Table 2 and Figure 2 , about half of the LKB1 alterations in lung cancer cell lines are large intragenic deletions, most of which cannot be detected by common mutational screening of primary tumors. Second, in primary tumors the admixture of nonmalignant cells also hinders the detection of point mutations, and small insertions and deletions (indels). Consistent with this, in lung cancer, we and others have observed higher rates of LKB1 mutation in cell lines than in primary tumors (Sanchez-Cespedes et al., 2002; Carretero et al., 2004; Matsumoto et al., 2007) . This would not be the case, however, for pancreatic cancer, Role of LKB1 in sporadic tumors M Sanchez-Cespedes where all the primary tumors examined were xenograft samples and the mutation frequency of LKB1 is far lower than that of the lung (Su et al., 1999) . Although the risk for pancreatic cancer is strongly increased in PJS patients, the low frequency of LKB1 mutations in the sporadic cases may indicate that other components of the LKB1 pathway are preferentially altered in these tumors.
It is crucial to fill these gaps in our knowledge of tumor biology. In addition, in the era of targeted therapies, these obstacles may have dire consequences for the selection of patients for future individualized treatments based on the presence of specific gene mutations. Thus, in the coming years, the development of novel technologies that allow accurate molecular diagnosis of heterogeneous cancer specimens will be a Abbreviations: AC, adenocarcinoma; LCC, large-cell carcinoma; PT, primary tumor; SCC, squamous cell carcinoma; SCLC, small-cell lung cancer. a Numbering is according to the coding DNA starting at the A of the start codon. b Mutations or residues reported also to be altered in tumors from PJS patients.
M Sanchez-Cespedes major challenge. Considerable effort is already being made in this regard, as exemplified by microreactorbased pyrosequencing, by which low-abundance oncogene mutations may be detected in complex samples with low tumor content (Thomas et al., 2006) .
Genetic profile of LKB1 mutations in sporadic lung cancer
The mutational pattern of LKB1 in lung tumors of sporadic origin is that of a classical tumor-suppressor gene. First of all, mutations are homozygous, as predicted by Knudson's two hit hypothesis (Knudson, 1971) . Second, a large proportion of mutations lead to the generation of truncated proteins, indicative of an inactivating event. Third, the mutations in tumors of sporadic origin arise somatically, and so are only present in the tumor tissue. Table 2 summarizes the LKB1 mutations found to date in lung tumors. As indicated, there is a large proportion of nonsense, indel frameshift mutations, large deletions and intronic mutations in splicingconserved sites (Figure 2 ). These changes lead to the generation of truncated and, therefore, inactive LKB1 proteins. Remarkably, of the 51 known mutations in lung tumors, only five are amino-acid substitutions, and all of these are located in the kinase domain of the protein (Figures 2a and b) . Missense mutations in this region abolish the ability of LKB1 to autophosphorylate (Mehenni et al., 1998; Ylikorkala et al., 1999) or to phosphorylate AMP-activated protein kinase (AMPK), a direct LKB1 substrate (Hawley et al., 2003) . Similar to PJS, LKB1 mutations in lung tumors are scattered throughout exons 1-8, and no mutations have been identified in exon 9. The LKB1 mutational profile in lung tumors includes the presence of mutations in exon 8 that retain the kinase activity but lack the C-terminal regulatory domain. Recurrent mutations such as the Q37X, the 837-842delC and frameshift indels at codons 51-53, also reported in PJS patients, are mutational hot spots. LKB1 deletions involving one or more exons, common in PJS, are also present in lung tumors. These abnormalities account for about half of the LKB1 alterations in lung cancer cell lines. The frequency of such deletions is considerably lower in lung primary tumors, probably due to the masking effect of mixed normal DNA.
The mutational signature of LKB1 in lung tumors is illustrated in Figure 2c . There is a high prevalence of GC:TA and GC:AT substitutions among the six types of nucleotide substitutions. Although a large number of mutations would be needed to be confident of the conclusion, the high percentage of GC:TA substitutions may reflect the influence of polycyclic aromatic hydrocarbon adducts from tobacco carcinogens, similar to what happens with KRAS and TP53 mutations in lung tumors (Ahrendt et al., 2001; Hainaut and Pfeifer, 2001) . Consistent with this explanation, most lung * * * * * * * ^ * * * + * * * ^ * Role of LKB1 in sporadic tumors M Sanchez-Cespedes tumors with LKB1 mutations are from smokers (Matsumoto et al., 2007) . LKB1 mutant tumors also carry concomitant mutations at other cancer genes such as KRAS, TP53, EGFR and p16, indicating that their role in carcinogenesis is not functionally equivalent (Sanchez-Cespedes et al., 2002; Matsumoto et al., 2007) .
LKB1 mutations accumulate in NSCLC as compared to small cell lung cancer. The loss of LKB1 protein during the development of lung adenocarcinomas has also been evaluated. Immunostaining of LKB1 in adenomatous atypical hyperplasia, the proposed precursor lesions for the adenocarcinomas of the lung, shows that loss of protein expression is already observed in severe dysplasia, suggesting that LKB1 inactivation occurs early on in the development of this type of lung cancer (Ghaffar et al., 2003) .
LKB1 as an energetic checkpoint controller
Functionally, the tumor-suppressor role of LKB1 is indicated by its ability to suppress the growth of tumor cells (Tiainen et al., , 2002 Marignani et al., 2001; Jimenez et al., 2003) , or to bring about apoptosis through its physical interaction with p53 (Karuman et al., 2001) . LKB1 has also been implicated in angiogenesis (Ylikorkala et al., 2001) and in the regulation of cyclooxygenase 2 levels through the regulation of the levels of the transcription factor PEA3 (Rossi et al., 2002; Upadhyay et al., 2006) . Knock-out LKB1 mice are lethal in embryos, whereas the heterozygous counterparts have a PJS-like phenotype, highlighting the critical role of LKB1 in cell growth and survival (Ylikorkala et al., 2001; Miyoshi et al., 2002; Nakau et al., 2002) .
LKB1 functions in a heterotrimeric complex with the inactive pseudokinase, STE20-related adaptor, and the armadillo repeat scaffolding-like protein, MO25 Boudeau et al., 2003) . The best characterized LKB1 substrate is the AMPK, a sensor of cellular energy status (Hawley et al., 2003) . An increase in the intracellular AMP/ATP ratio triggers the phosphorylation and activation of AMPK and subsequently modulates the activity of multiple downstream targets in normalizing ATP levels (Hardie, 2003) . Among these targets is the tuberin protein, the product of the tuberous sclerosis complex 2 gene (TSC2) that leads to the repression of mTOR (Corradetti et al., 2004; Shaw et al., 2004) . Germline mutations of TSC1 or TSC2 genes cause the tuberous sclerosis syndrome, which shares similarities with PJS, including the presence of hamartomas (Consortium TECS, 1993) . We recently confirmed that wild-type LKB1 is also required for modulating AMPK activity and therefore that of AMPKdownstream targets, including mTOR, in energetically depleted lung cancer cells (Carretero et al., 2007) . The identification of AMPK as a key substrate of LKB1 kinase activity provides definitive evidence that the abrogation of energetic checkpoints, probably with the purpose of maintaining energetically costly processes such as DNA replication and cell division, is an obligatory event for cancer development. LKB1, however, functions as a master upstream protein kinase of many AMPK-related kinases (Lizcano et al., 2004) , indicating that LKB1 modulates other important cell processes. Some of these AMPK-related kinases are the MAP/microtubule affinity-regulating kinases (MARK1, MARK2, MARK3 and MARK4) involved in microtubule stabilization, which may be related with the proposed role of LKB1 in cell polarity. Supporting this, LKB1 is homologous to the Par-4 genes of Caenorhabditis elegans, essential for establishing anterior-posterior (A-P) axis during embryonic development (Guo and Kemphues, 1995) , and to the Drosophila lkb1, also required for the early A-P polarity of the oocyte, and for the repolarization of the oocyte cytoskeleton that defines the embryonic A-P axis (Martin and St Johnston, 2003) . In mammalians, LKB1 induces complete polarization of intestinal epithelial cells in a cellautonomous fashion (Baas et al., 2004) . For a better understanding of the roles of LKB1 as an energetic checkpoint controller and in cell polarity, we refer the reader to several excellent recent reviews (Spicer and Ashworth, 2004; Alessi et al., 2006; Katajisto et al., 2007) . In addition, other LKB1 substrates are known and others will surely be found in the upcoming years that will help to understand other cell processes modulated by LKB1.
Conclusions
The frequency and type of LKB1 gene inactivation unequivocally attests to its tumor-suppressor role in lung tumorigenesis and demonstrates its significance in cancer development in other circumstances that merely the cancer-prone PJS. In addition to lung cancer, the use of highly sensitive screenings for mutations and large deletions may reveal that LKB1 gene alterations occur in a broad range of tumor types. Finally, the critical involvement of LKB1 in energetic control checkpoints highlights the importance of these processes in carcinogenesis and provides novel potential targets for gene screening in tumors and for therapeutic intervention.
